Over the last 2 years, Zim labs’ Operating Income, EBITDA and PAT for the company has grown at a CAGR of 9.6%, 29% and 110% respectively.
MUMBAI, Nov 23 (The CONNECT) – Drug delivery solutions provider ZIM Laboratories Ltd will get listed on the National Stock Exchange tomorrow.
ZIM Laboratories which already listed on the BSE since June 2018 has provided over 85% return to its investors from the listing price.
According to the shareholding pattern available on BSE as of September, the company’s promoters own 33.26% stake in the company of which, Dr. Anwar Daud, Chairman and Managing Director owns 27.37% stake and Mathew Cyriac, Executive Chairman of Florintree Advisors as an investor, owns 21.86% stake.
The company has multiple innovative process technologies like Micro Emulsion Coating Technology (MECT) (Liquid In Pellets), Pellet Cold Forming Technology(PCFT), Rapid Gelation Drug Release Technology(RGDCT), Matrix Pore Forming Tablet Technology(MAPOTAB) etc., which it leverages to develop innovative generic pharmaceutical products including Oral Thin Films (OTF) using its patented Thinoral® technology. With a clear focus on growing its R&D capabilities, the company has been regularly investing in R&D and in H1FY23 has invested 7.3% of its total operating income into research initiatives.
Leveraging on its R&D strength, ZIM uses its proprietary technology platforms for developing, manufacturing and supplying of differentiated generic pharmaceutical and nutraceutical products in Finished Formulations (FF) as well as Pre-Formulation Intermediates (PFI) in various therapeutic categories which include Anti-Infective, Cardiovascular System, Gastrointestinal, Analgesic / NSAID, Urology, Vitamins and Dietary Supplements etc.
Over the last 2 years (FY20 to FY22), Operating Income, EBITDA and PAT for the company has grown at a CAGR of 9.6%, 29% and 110% respectively. For the half year ending September 2022 (H1FY23), Operating Income grew 35.6% to Rs. 192 crores against Rs. 141 crores for the same period last year (H1FY22). EBITDA for H1FY23 grew to Rs 26.8 crores Vs Rs 17.6 crores in H1 FY22 and Net Profit was at Rs. 10.6 crores in H1 FY23 Vs Rs 3.45 crores in H1 FY22. Borrowings has also reduced from Rs 86.4 crores in H1 FY22 to Rs 63.3 crores in H1 FY23. On 12th November 2022, the Company also announced bonus issue of 2 shares for every 1 share held, subject to shareholder and other statutory approvals.
Dr. Anwar S. Daud, an M. Pharm and Ph.D in pharmaceutical chemistry and pharmaceutics respectively, established ZIM Laboratories Limited in 1989.
India is a crucial supplier of generic drugs, supplying to address almost 40% of the total U.S. generic drug (formulation) demand and approximately 25% of the total drug demand in the United Kingdom. India's domestic healthcare market is growing rapidly and is projected to grow at a CAGR of 8% to 10% from 2022 to 2026. In addition to improving private insurance coverage and greater willingness to spend on healthcare, government policies provide catalytic stimuli.